Advanced Metastatic Pancreatic Cancer: A Practical Guide to Tailoring First-line Therapy

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: February 19, 2016
Expiration Date: February 19, 2017

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

This activity will focus on clinical strategies for tailoring treatment to the unique needs of individual patients with pancreatic cancer, based on patient characteristics, and safety and efficacy profiles. It will discuss therapies beyond gemcitabine monotherapy, and address other recommended options for first-line treatment, including FOLFIRINOX and gemcitabine combinations with nab-paclitaxel, erlotinib, and other agents. Clinical pearls will focus on strategies for selecting the most appropriate agent or regimen from the recommended treatment options.

Target Audience

This activity is designed for community oncologists, pharmacists, and allied health care professionals who may provide care to patients with pancreatic cancer.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • List current therapeutic approaches for first-line treatment of metastatic, unresectable pancreatic cancer

  • Correlate treatment options for advanced metastatic pancreatic cancer with the patient types most appropriate for each

  • Outline a practical strategy for identifying the most appropriate first-line treatment option for metastatic pancreatic cancer based on disease stage, patient characteristics, mode of administration, and the safety and efficacy of each option


Advanced Metastatic Pancreatic Cancer: A Practical Guide to Tailoring First-line Therapy – Philip A. Philip, MD, PhD, FRCP

Instructions for Participation and Credit

This activity is eligible for credit through February 19, 2017. After this date, this activity will expire and no further credit will be awarded.
1. Read the target audience, learning objectives, and faculty disclosures.
2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
3. Complete the educational content as designed.
4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
6. Certificates for CME credit may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Philip A. Philip, MD, PhD, FRCP
Professor of Oncology and Internal Medicine
Dr. Kathryn Cramer Endowed Chair in Cancer Research
Leader, GI & Neuroendocrine Multidisciplinary Team
Vice President for Medical Affairs
Barbara Ann Karmanos Cancer Institute
Wayne State University School of Medicine
Detroit, Michigan

Dr. Philip Philip received his medical degree from the University of Baghdad, College of Medicine in Iraq, and his PhD in clinical pharmacology and pharmacogenetics at the University of London Guy’s Hospital Medical School in the UK. He completed a residency at the University of Baghdad, and a fellowship in medical oncology at the University of Oxford and the MD Anderson Cancer Center in Houston, Texas. Dr. Philip is a professor of oncology and medicine at the Wayne State University School of Medicine and the Karmanos Cancer Center. He is the leader of the GI & neuroendocrine multidisciplinary team and vice president for medical affairs at the Karmanos Cancer Institute, as well as the Kathryn Cramer MD Endowed Professor in Cancer Research at Wayne State University School of Medicine in Detroit

Dr. Philip is USA board-certified in medical oncology and a fellow of the Royal College of Physicians in the UK. He chairs the pancreatic cancer committee at the Southwest Oncology Group (SWOG) and is a member of the International Liver Cancer Association and the American Society of Clinical Oncology.

A frequent national and international lecturer, Dr. Philip authored over 200 manuscripts, review articles, editorials, and co-edited a book on pancreatic cancer. His major research interests are in the development of new therapies for gastrointestinal and neuroendocrine cancers with a special focus on pancreatic cancer. He has been the principal investigator on numerous local and national clinical trials in GI cancers.


MediCom WOrldwide, Inc. CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.5 contact hours of Continuing Education Credit. Universal Activity Number: 0827-0000-16-067-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.


As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Philip Philip has received consultant fees from Amgen Inc., Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Clovis Oncology, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Genomic Health, Inc., Gilead, Halozyme, Inc., Novartis AG, Onyx, and sanofi-aventis U.S. LLC.; honoraria related to formal advisory activities from Boehringer Ingelheim, Celgene, Gilead, MedImmune, LLC, Merrimack Pharmaceuticals, Inc., Novartis; as well as speakers’ bureau activities from Amgen, Bayer, Celgene, Eli Lilly, F. Hoffmann-La Roche, Genentech, Inc., Novartis, Onyx, and Sanofi. He has received grant support related to research activities from Abbott, Bayer, Bristol-Myers Squibb, Celgene, Eli Lilly, F. Hoffmann-La Roche, Incyte, Nektar, and Novartis

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, executive director, has no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is independently peer reviewed for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

Off-Label Disclosures/Investigational Disclosures

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Further, attendees/participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program.

Dr. Philip has indicated that he does intend to discuss off-label uses of drugs, mechanical devices, biologics or diagnostics approved by the US Food and Drug Administration (FDA) for use in the US.

Dr. Philip has indicated that he does intend to discuss investigational drugs, mechanical devices, biologics or diagnostics not approved by the FDA for use in the US.

Hardware/Software/Internet Requirements

MediCom Worldwide, Inc. requires Internet Explorer® version 9.0 or higher, the latest version of Google Chrome, or the latest version of Safari, a computer running Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may include Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player, and/or Microsoft® Silverlight™.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Celgene Corporation and Incyte Corporation.

©2016 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

MediCom Worldwide, Inc. would like to thank Celgene Corporation for their educational support of

©2020 MediCom Worldwide, Inc. All rights reserved